Novel Insights in Advanced Thyroid Carcinoma: From Mechanisms to Treatments

Advanced thyroid carcinoma is rare, but accounts for most of the disease-related morbidity and mortality.

The recent increase in our knowledge of its molecular genetics and biology, as well as the progress in conducting multicenter clinical trials, are beginning to unlock unique opportunities to better understand aggressive thyroid cancers. Ultimately, this will lead to novel treatment approaches, some of which are already in the pipeline.

This European Thyroid Journal collection aims to provide state-of-the-art information on the biological underpinnings, current treatments and novel translational research in advanced thyroid carcinoma.

Topics of interest include, but are not limited to:

mutation-induced mechanisms of thyroid cancer progression
targeted therapies and immunotherapies in the adjuvant or neoadjuvant setting for differentiated and anaplastic thyroid cancers
redifferentiation strategies for patients with metastatic, radioiodine-refractory differentiated or poorly differentiated thyroid tumors
epidemiology of high-risk thyroid cancer
genomic and metabolomic foundations of oncocytic thyroid cancers
mechanisms of resistance to multi-kinase and mutation-specific inhibitors
development of pre-clinical models to study aggressive thyroid cancers.

We believe that this collection can mark a milestone in our knowledge of advanced thyroid carcinoma, providing a key resource for the community of researchers and clinicians involved in the study of this disease.

Collection Editors

	Professor Efisio Puxeddu, MD, PhD Professor Puxeddu is Associate Professor of Endocrinology at the Department of Medicine and Surgery of the University of Perugia, Italy. He is Residency Program Director, at the Hospital of Perugia and Director of the Section of Endocrinology and Metabolism. For over 20 years, he has been performing clinical and translational research activity in the field of thyroid carcinoma. More recently, his research has been concentrated on dissecting the molecular mechanisms involved in the development of hot and cold thyroid carcinoma immunophenotypes, on novel treatment modalities for anaplastic thyroid carcinoma and on Tyrosine Kinase Inhibitors clinical efficacy and side effects.
	Professor Iwao Sugitani, MD, PhD Professor Sugitani is a Graduate School Professor & Chairman of the Department of Endocrine Surgery at Nippon Medical School in Tokyo. His main area of research focuses on clinical studies for thyroid cancer, including active surveillance of low-risk papillary microcarcinoma, risk stratification of papillary thyroid carcinoma, and clinical trials for anaplastic thyroid carcinoma.
	Dr Iñigo Landa, PhD Dr Landa is an Associate Scientist in the Division of Endocrinology at Brigham and Women’s Hospital, and an Assistant Professor of Medicine at Harvard Medical School in Boston. The focus of Dr. Landa’s lab is to identify and understand the mechanisms of key genetic events in thyroid cancer progression.